Angiosarcomas

Conventional heart drug stops progression of cancer

A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study by researchers at Texas Tech University Health Sciences Center (TTUHSC) El Paso.

Brad Bryan, Ph.D., an assistant professor at TTUHSC El Paso, is studying novel...
Brad Bryan, Ph.D., an assistant professor at TTUHSC El Paso, is studying novel therapeutic strategies to treat the aggressive cancer angiosarcoma.
Source: Texas Tech University Health Sciences Center El Paso
Brad Bryan, Ph.D., is studying how the common heart drug propranolol may stop...
Brad Bryan, Ph.D., is studying how the common heart drug propranolol may stop the progression of angiosarcoma, a highly lethal cancer of the blood vessels.
Source: Texas Tech University Health Sciences Center El Paso

Angiosarcomas are highly lethal tumors that can occur in any part of the body. The tumor typically appears as a growth or lesion on the skin; the larger the growth, the greater the risk of mortality.

In 2014, Brad Bryan, Ph.D, an assistant professor at TTUHSC El Paso’s Center of Emphasis in Cancer, and William Chow, D.O., a dermatological oncologist at Mohs Micrographic Surgery and Cutaneous Oncology, treated a man with an enlarging lesion on his left cheek, forehead and scalp. Biopsy revealed it was angiosarcoma, and the case didn’t look good.

“We were presented with a patient exhibiting a rapidly expanding uniformly fatal tumor with no realistic options for a favorable outcome based on current standard treatments,” the two researchers wrote in their study.

Previous research in Bryan’s lab suggested that propranolol — a drug that’s typically used for high blood pressure — might be effective against angiosarcomas, so Chow and Bryan proceeded to use the medication to treat the patient.

After one week of the propranolol treatment, the tumor ceased its rapid expansion and showed no evidence of clinical enlargement or extension. Within six months of use of propranolol — and eventually, added chemotherapy and radiation — the patient’s tumor was undetectable. The results are published in the journal JAMA Dermatology.

The finding is not only promising against cancer, but for patient finances. Current prescription drug therapies for sarcomas can cost patients more than $10,000 a month. Propranolol, however, costs about $4 a month.

“If this finding extends to a broader patient population, administration of propranolol may be a major advancement in the treatment of angiosarcomas,” Bryan and Chow write.


Source: Texas Tech University Health Sciences Center El Paso

27.11.2015

Read all latest stories

Related articles

Photo

Stroke treatment

Six international studies endorse thrombectomy

Results from six international randomised controlled studies conclusively and uniformly confirm, for the very first time, the effectiveness of thrombectomy in patients with acute, severe ischaemic…

Photo

Drug delivery, microsurgery

Microbots show promise in tumor treatment

Targeting medical treatment to an ailing body part is a practice as old as medicine itself. A Band-Aid is placed on a skinned knee. Drops go into itchy eyes. A broken arm goes into a cast. But often…

Photo

Micro-constrictions

Reducing damage after a heart attack

Researchers in the Medical Sciences Division of Oxford University have established a key cause of micro blood vessels constricting during surgery to reopen a blocked artery, and identified a…

Related products